CMS is requiring prescription drug manufacturers that report average sales price (ASP) data to use a new automated system, beginning with the second quarter 2018 ASP data submission (due April 30, 2018). To help manufacturers navigate the new system, CMS is hosting a March 27, 2018 educational call, which will include a question and answer session. Registration is required to participate in the call.
CMS is seeking comments on its proposed updates to the methodologies used to pay Medicare Advantage (MA) and Part D plan sponsors for 2019. This year CMS released its 2019 Advance Notice and Draft Call Letter in two parts. In late 2017, CMS released proposed changes to the Part C risk adjustment model (Part I of the Advance Notice) to comply with new 21st Century Cures Act requirements. Part II of the Advance Notice and Call Letter, released earlier this month, includes proposed rate updates and various policy provisions. According to a CMS fact sheet, the update would increase plan payments by 1.84% relative to 2018, without taking into account an adjustment for underlying coding trend, which CMS expects to increase risk scores by 3.1% on average. Continue Reading
CMS has set the dates for its annual meetings to discuss applications for new and revised HCPCS codes:
May 14-17, 2018: Drugs, Biologicals, Radiopharmaceuticals, Radiologic Imaging Agents
June 5-6, 2018: Durable Medical Equipment and Accessories, Orthotics and Prosthetics, Supplies, Other [note that the Federal Register includes two sets of dates for this session; we have confirmed that the meetings are June 5 and 6]
Additional information, include preliminary coding determinations, will be posted at least four weeks before each meeting on the CMS HCPCS website.
CMS is hosting a call on March 21, 2018 to get feedback from physicians and non-physician practitioners on Evaluation and Management (E/M) services. According to the CMS announcement, the agency is looking for information from stakeholders on how the E/M guidelines can be updated “to reduce burden and better align coding and documentation with the current practice of medicine.”
The Trump Administration has issued a potentially highly-significant proposed rule intended to expand the availability of short-term, limited duration insurance policies that are exempt from Affordable Care Act (ACA) qualified health plan standards. Under the proposed rule, issued by the Departments of Treasury, Labor, and Health and Human Services (the “Departments”), the maximum duration of this “short-term” coverage would be extended from less than three months to less than 12 months (taking into account any extensions that may be elected by the policyholder without the issuer’s consent). The contract and application materials for these short-term, limited-duration plans would be required to include standard notices to inform the public that the plans are not required to comply with federal requirements for health insurance (principally those in the ACA), and additionally, for those policies having a coverage start date prior to January 1, 2019, that they do not provide minimum essential coverage and the beneficiary may have to make a payment as a consequence (i.e., the ACA individual responsibility payment). The proposal states that the premiums for these ACA non-compliant plans are likely to be lower than those for ACA-compliant plans, citing one report showing a difference of $124 per month vs. $393 per month in average monthly premiums for such plans in the fourth quarter of 2016. The ACA requirements with which issuers of these plans are not required to comply include prohibitions on denying coverage to persons with preexisting conditions and on varying premiums based upon health status, requirements to cover essential health benefits, restrictions on average and lifetime benefit caps, and guaranteed renewability, among others. As such, issuers of such policies would be permitted to engage in “medical underwriting” (referred to in the proposal as pricing “in an actuarially-fair manner (by which the Departments mean that it is priced so that the premium paid by an individual reflects the risks associated with ensuring the particular individual or individuals covered by that policy).” Moreover, the issuer could refuse to renew policies for beneficiaries who develop chronic health care conditions. The Departments noted that these changes may impact individual market risk pools for ACA-compliant plans, but they estimate that in 2019 only 100,000 – 200,000 individuals will elect to enroll in short-term, limited duration plans after this change; the Departments seek comments on these estimates, as well as on various other aspects of the proposed rule. Comments on the proposed rule will be accepted until April 23, 2018.
A number of recent Congressional hearings focused on federal health policies, including the following:
- House Energy and Commerce Committee hearings on the impact of health care consolidation, oversight of the Department of Health and Human Services (including the Trump Administration’s HHS budget request), and drug compounding.
- Ways and Means Committee hearings on President Trump’s HHS budget request and opioid abuse in the Medicare population.
- A Senate Finance Committee hearing on the President’s HHS budget proposal.
- A Senate Health, Education, Labor & Pensions (HELP) Committee hearing on the impact of the opioid crisis on children and families.
- A Senate Aging Committee hearing on rheumatoid arthritis therapies.
Additional hearings are also scheduled over the next few days, including:
- A February 27 HELP Committee hearing on “The Opioid Crisis: The Role of Technology and Data in Preventing and Treating Addiction.”
- A February 28 Energy & Commerce hearing on “Combating the Opioid Crisis: Helping Communities Balance Enforcement and Patient Safety.”
- A March 1 Energy & Commerce hearing on implementation of the Merit-based Incentive Payment System.
CMS is hosting a call on March 13, 2018 to discuss the status of the “Low Volume Appeals” (LVA) settlement process and upcoming submission timeframes. As previously reported, this option is available for appellants with fewer than 500 total Medicare Part A or Part B claim appeals pending at the Office of Medicare Hearings and Appeals and the Medicare Appeals Council at the Departmental Appeals Board as of November 3, 2017 with a total billed amount of $9,000 or less per appeal, subject to other conditions. Eligible appeals will be settled at 62% of the net allowed amount. A question and answer session will follow the presentation. Registration information is available here.
The new Bipartisan Budget Act of 2018 (the Act), recently signed into law by President Trump, includes extensive Medicare, Medicaid, and other health policy and payment provisions. Policy changes that will be welcome to health care providers and manufacturers include: repeal of the Independent Payment Advisory Board (IPAB); elimination of the Medicare outpatient therapy caps; Stark Act revisions; and extension of various expired Medicare payment provisions. On the other hand, the Act includes significant Medicare and Medicaid offsets, such as: reduced Medicare provider payment updates; increased Medicaid rebate obligations with respect to line extension drugs; cuts in Medicaid disproportionate share hospital allotments; changes to manufacturer discount obligations in the Medicare Part D “donut hole”; and inclusion of hospice care in the hospital post-acute transfer policy. Moreover, the Act once again significantly increases penalties for violations of various anti-fraud statutes.
Reed Smith has prepared a Client Alert focusing on the major Medicare, Medicaid, and public health provisions of the Act; the Alert is available here.
The Trump Administration has released its fiscal year (FY) 2019 budget proposal, which includes extensive health policy provisions. While most of the President’s policy proposals for Department of Health and Human Services (HHS) programs would require Congressional approval, others are characterized as administrative proposals that presumably would not involve Congress. Continue Reading
CMS will not proceed with its planned Direct Decision Support (DDS) innovation model “due to operational and technical issues with the proposed Model design.” When this model was announced in December 2016, it was expected to test a shared decision-making approach outside of the clinical delivery system. On February 2, 2018, CMS announced that it has determined that “design and operational changes necessary to continue with the DDS Model would be too significant and burdensome for participants, and would require a new solicitation.” This announcement follows cancellation of the higher-profile planned cardiac/hip fracture episode payment model and cardiac rehabilitation incentive payment models.
Cancellation of the DDS initiative suggests that the Trump Administration’s recent launch of its first innovation model — Bundled Payments for Care Improvement Advanced — does not mean that the Administration has embraced other innovation models in the pipeline.
As previously reported, CMS has initiated a “low volume appeals (LVA) settlement” option as part of broader HHS efforts to improve the Medicare appeals process. This option is available for appellants with fewer than 500 total Medicare Part A or Part B claim appeals pending at the Office of Medicare Hearings and Appeals and the Medicare Appeals Council at the Departmental Appeals Board as of November 3, 2017 with a total billed amount of $9,000 or less per appeal, subject to other conditions. Eligible appeals will be settled at 62% of the net allowed amount.
CMS is hosting a call on February 13, 2018 to discuss the status of the LVA process and explain how to identify claims that are eligible for settlement. A question and answer session will follow the presentation. Registration is required to participate in the call.
The Department of Veterans Affairs (VA) and the Centers for Medicare & Medicaid Services (CMS) have announced a partnership to leverage CMS’s program integrity tools to detect and prevent fraud within VA programs. The collaboration will focus on applying state-of-the-art data analytics tools and best practices identified by CMS to VA claims payment processes. In addition to capitalizing on the lessons learned by CMS, the VA has also indicated that it will invite industry experts to demonstrate their capabilities for detecting and preventing fraud, waste, and abuse and recovering improper payments later this spring.
Alex Azar was sworn in as Secretary of Health and Human Services on January 29, 2018. He fills the position left by former Secretary Tom Price, M.D., who resigned last fall in the wake of a controversy over his travel expenses.
A top Department of Justice (DOJ) official has recently issued a much-anticipated memo explaining the factors DOJ will consider when deciding whether to dismiss FCA suits brought by relators in qui tam cases. Specifically, the memo by Michael Granston, Director of the Commercial Litigation Branch within the DOJ Fraud Section sets forth seven non-exhaustive factors that DOJ lawyers should consider when deciding whether to seek dismissal of all or part of a FCA qui tam suit under 3730(c)(2)(A), addressing the following areas:
- Curbing meritless qui tams
- Preventing parasitic or opportunistic qui tam actions and controlling litigation
- Preventing interference with agency policies and programs
- Certain procedural and policy concerns
In addition to keeping the federal government operating through February 8, 2018, the newly-enacted Continuing Appropriations Act provides temporary relief from three health-related taxes imposed by the Affordable Care Act (ACA) and funds the Children’s Health Insurance Program (CHIP) through fiscal year 2023. With regard to the ACA taxes, the Continuing Appropriations Act:
- Imposes a two-year moratorium on the ACA’s 2.3% excise tax on the sale of medical devices. The device tax will not apply to sales during calendar years 2018 and 2019.
- Delays for two years the excise tax on certain high-cost employer-sponsored health coverage (the so-called “Cadillac tax”). Under the law, the tax will be effective in 2022 rather than 2020.
- Provides a one-year moratorium on the annual excise tax imposed on health insurers, applicable to calendar year 2019.
Since the Continuing Appropriations Act only keeps the government open for less than three weeks, Congress will be facing another budget deadline in the near future. It is anticipated that there will be a push to use the next funding bill as an opportunity to address a number of expired Medicare payment and policy provisions (often called “extenders”), such as the extension of the outpatient therapy cap exceptions process.
The House Energy and Commerce Health Subcommittee voted to approve the following health policy bills on January 18, 2017:
- H.R. 2026, the Pharmaceutical Information Exchange (PIE) Act. This bill would create a safe harbor that would allow drug and medical device companies to share certain health care economic or scientific information with payers, formularies, and other coverage, reimbursement, and population-based health care decision makers prior to FDA approval. Such information – including clinical and pre-clinical data and results relating to an unapproved drug therapy, or drug indication, or other condition of use being investigated or developed – must be based on competent and reliable scientific evidence and relate to an investigational use of a new drug or device or an investigational use of an approved drug or device. The safe harbor would allow for such information to be shared only if a supplemental application has been submitted to FDA for such use or, at a minimum, the study or studies needed to support the submission of a supplemental application have been completed “with the intention that a supplemental application will be submitted to [FDA] for approval of the use.” The bill was approved by a vote of 18 to 14. If it becomes law, H.R. 2026, the PIE Act, would partly codify current FDA policy governing pre-approval communications with payors, formulary committees, and similar entities. FDA’s policy, announced in a draft guidance issued January 2017 (Drug and Device Manufacturer Communications with Payors, Formulary Committees, and Similar Entities – Questions and Answers), states that pre-approval information “may help payors plan and budget for future coverage and/or reimbursement decisions prior to FDA approval of investigational products,” The policy also clarifies that FDA “does not intend to object” to the dissemination of this information under 21 C.F.R. § 312.7(a). FDA’s policy permits the following information to be disclosed pre-approval: (1) product information (e.g., drug class); (2) information about the indication sought, such as information from the clinical study protocol(s) about endpoint(s) being studied and the patient population under investigation (e.g., number of subjects enrolled, subject enrollment criteria, subject demographics); (3) factual presentations of results from clinical or preclinical studies (i.e., no characterizations or conclusions should be made regarding the safety or effectiveness of the product); (4) anticipated timeline for FDA action and/or possible FDA approval; (5) product pricing information; (6) targeting/marketing strategies (e.g., outreach activities planned to generate prescriber awareness about the product); and (7) anticipated product-related programs/services (e.g., patient support programs, including information about copay/savings cards).
- H.R. __, the Over-the-Counter Monograph Safety, Innovation, and Reform Act. The legislation would make what many consider to be long-overdue reforms to the FDA over-the-counter (OTC) monograph program for nonprescription drugs marketed without an approved new drug application. To modernize and streamline the process, the legislation would create a system for future changes to drug monographs through an administrative order procedure with the opportunity for development meetings or other consultations, submission of comments on proposed orders, and dispute resolution procedures. To enhance public health, the legislation would create a mechanism for faster safety label changes, and establish a pathway for innovations under monographs. The bill would establish an OTC monograph user fee program to support related reforms. The bill was approved by a voice vote.
- H.R. 1876, the Good Samaritan Health Professionals Act. This bill would provide limited liability protection for health care professionals providing services as a volunteer during a federally-declared disaster. The bill was approved by a voice vote.
The bills now advance to the full Energy and Commerce Committee.
The Substance Abuse and Mental Health Services Administration (SAMHSA) has issued a final rule addressing the disclosure of substance use disorder patient records that is intended to facilitate health care activities while protecting patient privacy. The final rule identifies the circumstances under which lawful holders of patient identifying-information may disclose such information to their contractors, subcontractors, and legal representatives to support payment, health care operations, and audit and evaluation activities. In addition, the final rule establishes an optional abbreviated notice of the prohibition on redisclosure that must accompany each disclosure made with the patient’s written consent. Finally, the rule makes a number of technical corrections to a related January 18, 2017 final rule. The rule is effective February 2, 2018.
The Office of the National Coordinator (ONC) for Health Information Technology has released a draft trusted exchange framework that proposes policies, procedures, and technical standards to further Congressionally-mandated efforts to establish a nationwide, interoperable health system under the 21st Century Cures Act of 2016. Currently, there are dozens of Health Information Networks (HINs) that operate locally, regionally, or nationally, but that do not exchange health information with each other. The draft framework focuses on principles for trusted exchange of electronic health information and minimum required terms and conditions for trusted exchange among the nation’s multiple health information networks. The trusted exchange framework aligns with HIPAA requirements, but also specifies terms and conditions to enable broader exchange of health information among both regulated (i.e., covered entities and business associates) and non-regulated entities. The framework indicates that additional and faster progress is necessary in developing interoperability, especially in the case of medical specialties—such as long-term services and supports providing post-acute care or in lieu of institutionalization, behavioral health, and other ambulatory services.
Public comments are being accepted electronically at firstname.lastname@example.org until February 18, 2018. Subsequently, the ONC will select a Recognized Coordinating Entity (RCE), which will develop a single common agreement that qualified health information networks and their participants may voluntarily agree to adopt. Following the comment period and refinements to the draft framework, HHS expects to release a final draft of the combined trusted exchange framework and common agreement later this year.
The Trump Administration has rolled out its first CMS Innovation Center Medicare bundled payment initiative, the Bundled Payments for Care Improvement Advanced (BPCI Advanced). Under the new voluntary model, CMS will test whether bundled payments for 29 inpatient and 3 outpatient clinical episodes will lead to reduced Medicare expenditures while improving quality of care for Medicare beneficiaries. CMS anticipates that the performance period of the BPCI Advanced model will begin on October 1, 2018 and run through December 31, 2023.
BPCI Advanced builds on the ongoing Bundled Payments for Care Improvement (BPCI) initiative, which was launched in 2013 and runs through September 30, 2018. As in the BPCI model, BPCI Advanced seeks to incentivize providers to coordinate care to furnish services more efficiently while maintaining quality. Specifically, participants may either realize a gain or loss depending both on (1) how successfully they manage total Medicare fee-for-service costs of care (with limited exceptions) throughout each 90-day episode of care and (2) performance on specified quality measures.
There are key differences between the original BPCI and BPCI Advanced models, including the following (among others): Continue Reading
CMS has announced a new initiative allowing states to propose demonstrations to “improve Medicaid enrollee health and well-being through incentivizing work and community engagement.” Specifically, states may propose Section 1115 waivers to make participation in work or other community engagement a requirement for continued Medicaid eligibility or coverage for non-elderly, non-pregnant adult Medicaid beneficiaries who are eligible for Medicaid on a basis other than disability. CMS explains the criteria it will use to evaluate state proposals, including: alignment with Temporary Assistance for Needy Families (TANF) and Supplemental Nutrition Assistance Program (SNAP) programs; population subgroups included in the demonstration (including observance of all federal civil rights laws); the proposed range of activities that would satisfy the work and community engagement requirement; the proposed beneficiary supports in meeting the new requirements; and local employment market conditions. CMS also specifies that any section 1115 waiver program must be budget neutral; states will not be permitted to accrue savings from an associated reduction in enrollment.
The day after announcing the new Medicaid option, CMS approved a Kentucky waiver allowing the state to implement a community engagement requirement as a condition of eligibility for Medicaid beneficiaries aged 19 to 64, with a number of exceptions (former foster care youth, pregnant women, primary caregiver of a dependent, beneficiaries considered medically frail, certain beneficiaries with acute medical conditions, and full time students). To remain eligible for coverage, non-exempt Medicaid recipients in Kentucky must complete 80 hours per month of community engagement activities (e.g., employment, education, job skills training, and community service).